Table 3.

Summary of lymphoma/lymphoproliferative disorder in phase II, III and LTE studies

Histology	EBV status	Demographics	Onset (days)	Tofacitinib dose*	Location
Large B cell lymphoma	Negative	78-year-old white female	818	5 mg twice daily+MTX	Central nervous system
Lymphoma c/w Hodgkin's	Positive	51-year-old Asian female	227	5 mg twice daily	Abdominal lymph nodes
Low-grade B cell lymphoma	IgG: ± and non-specific EBNA positive	47-year-old Asian female	220	10 mg twice daily+MTX	Thymus
Large B cell lymphoma	EBER positive in rare, scattered mononuclear cells	69-year-old white female	642	10 mg twice daily+MTX	Left breast, mediastinum and left axillary area
Large B cell lymphoma, Burkitt-like	EBER positive in small focus of cells	65-year-old white male	149	10 mg twice daily	Right submandibular gland—right neck
Small B cell lymphocytic lymphoma (mantle cell)	Negative	61-year-old white female	659 457	5 mg twice daily, 10 mg twice daily†	Tonsil
Non-Hodgkin's lymphoma (DCL lymphoproliferative disorder)	Negative	47-year-old white female	625	10 mg twice daily+MTX	Salivary gland
Low-grade non-Hodgkin's B cell lymphoma (CT guided lung biopsy)	N/A (no EBV report)	65-year-old white female	1621	5 mg twice daily+MTX	Lung
T cell chronic lymphocytic leukaemia	Negative	63-year-old white male	449	5 mg twice daily	Haematological
Non-Hodgkin's lymphoma	N/A (no EBV report)	71-year-old white female	723	5 mg twice daily	Generalised non-Hodgkin's lymphoma affecting bifurcational, para-aortic, peripancreatic and mesenteric lymph nodes, spleen and body of L3

See online supplementary appendix for more details of the lymphoma cases.

*Randomised treatment assignment.

†Patient was receiving 5 mg twice daily at time of event.

DCL, donor cell leukaemia; EBER, Epstein–Barr encoded ribonucleic acid; EBNA, Epstein–Barr nuclear antigen; EBV, Epstein-Barr virus; IgG, immunoglobulin G; LTE, long-term extension; MTX, methotrexate; N/A, not available.